Novavax’s Stock Rising, NVX‑CoV2373 Vaccine Against COVID-19 Receives Funds For Mass Production

On Thursday, NASDAQ: NVAX gained 0.93% reaching $44.66 but the daily trading volume could not beat the average volume of 9,828,631. Pre-market Friday price grows 15% to $51. Possibly, this market may double the daily volume.

The good news just came to Novavax’s stakeholders; the U.S. Department of Defense will finance $60 million a development of NVX‑CoV2373 which will go under mass production. DoD will test the vaccine in stage 2/3 clinical tests if the U.S. FDA approves it.

Related:  DSG Global (DSGT) Rockets 130% On 42 Million Shares

NVX‑CoV2373’s antibodies managed to stop the binding of spike protein to receptors in pre-clinical trials that were conducted by Novavax. Without being closely stuck onto receptors the virus can’t conquer the respiratory system. Therefore, weak protein covered virus soon may not survive inside the victim’s body. The immune system can neutralize COVID-19 slowly after it gets exhausted.

Asan Abdiev

CEO and Editor in Chief. Living in the era of dynamic tech change Asan decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring Finance) writing for technology and as well as finance has been one of the precious aspects of his life